35 resultados.
More than four million doses of the anti-COVID-19 vaccine Abdala were delivered to the Mexican Health Secretariat, after the arrival of a first batch to that country on Friday. The vaccine will be used in the ongoing immunization of the adult population, informed the BioCubaFarma Business Group.
When, at the end of July 2021, the anti-COVID-19 mass immunization with nationally produced vaccines created by our scientists began in Cuba, the daily positive cases of SARS-COV-2 amounted to 9,000, with thousands of accumulated deaths and more than 40,000 active patients with the virus, in the midst of a complex epidemiological situation that hit Cuban families.
It is Friday, family visit day in the José Martí Integral Formation School (EFI in Spanish), attached to the Ministry of the Interior (MININT).
The vaccine candidate Mambisa - developed by the Center for Genetic Engineering and Biotechnology (CIGB) - is currently in the final stages of clinical trials and, based on the results obtained in the analyses, will apply to the Center for State Control of Medicines, Equipment and Medical Devices for authorization for emergency use as a booster dose in the next few weeks.
Clinical trials to evaluate the vaccine’s safety and effectiveness as a booster are being conducted at Cuba’s La Pradera International Health Center and the Amedeo di Savoia Hospital, in the Italian city of Turin
A 48-square-kilometer-long causeway connects Cuba's largest island with the keys of Villa Clara (made up of Las Brujas, Ensenachos and Santa María keys), part of the group of islands located to the north of this central province, which in the 1990s became a colossal tourist project led by Commander in Chief Fidel Castro Ruz
The administration of a third dose of candidate vaccine Abdala, as part of phase III clinical trials, has been completed and efficacy studies begin
Given the epidemiological situation around the world and the need to contain a new wave of COVID-19 cases in Cuba, new measures have been adopted, including the testing and isolation of all travelers arriving from abroad
The aim is to have a formulated vaccine candidate ready to be evaluated in animal models in 2023.
Mass vaccination in Cuba began precisely at a time when COVID-19 infections were increasing significantly, generating concerns within the population about the effectiveness of our nationally developed vaccines.
